Effect of treatment on weight gain and metabolic abnormalities in patients with first-episode psychosis

References

• Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005; 162: 1785–1804
   PubMed Web of Science ®Google Scholar
• Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999; 156: 544–549
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991; 48: 739–745
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Mackeel JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004; 66: 51–57
   PubMed Web of Science ®Google Scholar
• Zipursky RB, Gu H, Green AI, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 2005; 187: 537–543
   PubMed Web of Science ®Google Scholar
• Perez-Iglesias R, Crespo-Facorro B, Amado JA, et al. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry 2007; 68: 1733–1740
   PubMed Web of Science ®Google Scholar
• Saddichha S, Manjunatha N, Ameen S, Akhtar S. Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. J Clin Psychiatry 2007; 68: 1793–1798
   PubMed Web of Science ®Google Scholar
• Addington J, Saeedi H, Addington D. Weight gain in first-episode psychosis over three years. Schizophr Res 2006; 86: 335–336
   PubMed Web of Science ®Google Scholar
• Strassnig M, Miewald J, Keshavan M, Ganguli R. Weight gain in newly diagnosed first-episode psychosis patients and healthy controls: one-year analysis. Schizophr Res 2007; 93: 90–98
   PubMed Web of Science ®Google Scholar
• First MB, Spitzer RL, Gibbon M. Structured clinical interview for DSM IV Axis I disorders, patient edition (SCID-P), version 2. New York State Psychiatric Institute, Biometrics Research, New York 1994
   Google Scholar
• Kay SR, Opler LA, Fiszbein A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–276
   PubMed Web of Science ®Google Scholar
• Sachs GS, Guille C. Weight gain associated with use of psychotropic medications. J Clin Psychiatry 1999; 60(Suppl 21)16–19
   PubMed Web of Science ®Google Scholar
• Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001; 62: 231–238
   PubMed Web of Science ®Google Scholar
• Homel P, Casey D, Allison DB. Changes in body mass index for individuals with and without schizophrenia, 1987–1996. Schizophr Res 2002; 55: 277–284
   PubMed Web of Science ®Google Scholar
• Russell JM, Mackell JA. Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs 2001; 15: 537–551
   PubMed Web of Science ®Google Scholar
• Safer DJ. A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol 2004; 24: 429–436
   PubMed Web of Science ®Google Scholar
• Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight liabilities. J Clin Psychiatry 1999; 60: 358–363
   PubMed Web of Science ®Google Scholar
• Umbricht DS, Pollack S, Kane JM. Clozapine and weight gain. J Clin Psychiatry 1994; 55(Suppl B)157–160
   PubMed Web of Science ®Google Scholar
• Lamberti JS. Is antipsychotic drug-induced weight gain associated with a favorable clinical response?. J Clin Psychiatry 2000; 61: 678
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Stensland M, Zhao Z, Kinon BJ. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry 2005; 5: 3
   PubMed Web of Science ®Google Scholar
• Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000; 157: 975–981
   PubMed Web of Science ®Google Scholar
• Meyer JM. A retrospective comparison of weight, lipid and glucose changes between risperidone- and olanzapine- treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 2002; 63: 425–433
   PubMed Web of Science ®Google Scholar
• Birkenaes AB, Birkeland KI, Engh JA, et al. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol 2008; 28: 132–137
   PubMed Web of Science ®Google Scholar
• Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 2001; 11: 25–32
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160: 290–296
   PubMed Web of Science ®Google Scholar
• Bushe C, Leonard B. Association between atypical antipsychotic agents and type-2 diabetes: review of prospective clinical data. Br J Psychiatry Suppl 2004; 47: s87–s93
   PubMedGoogle Scholar
• Wu RR, Zhao JP, Liu ZN, et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology 2006; 186: 572–578
   PubMed Web of Science ®Google Scholar
• Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002; 59: 337–345
   PubMed Web of Science ®Google Scholar